Some studies have reported that programmed death-ligand 1 (PDL1), tumor mutational burden (TMB), mismatch repair, and CD8+T cells may be potential biomarkers for efficacy prediction, whereas Janus kinase 1 (JAK1), JAK2, and beta-2-microglobulin truncation may be predictors of primary resistance (2–4). Here, JAK1 is linked to neoplasm.